FoxWayne Enterprises Acquisition Corp.
FOXWU
NASDAQ Capital Market10.24
USD
- -
- -
CIK
0001829999
ISIN
US35166L2088
CUSIP
35166L208
Return %
Stock
S&P500
1Y
0.59
26.53
3Y
-1.35
76.60
5Y
-1.35
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Robb Knie
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1 Rockefeller Plaza New York City NY United States of America 10020
- IPO Date
- Jan 20, 2021
- CIK
- 0001829999
- Website
- foxwayne.com
- Similar Companies
- Business
- FoxWayne Enterprises Acquisition Corp. (FOXWU) is a blank check company, or special purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Incorporated in 2020 and headquartered in New York, New York, the company targets opportunities primarily in the biotechnology and/or telemedicine sectors of the healthcare industry or the technology industry in North America; its core activities include raising capital through an initial public offering of units, holding proceeds in a trust account, sourcing potential targets, conducting due diligence, and structuring transactions pending shareholder approval, with units trading on OTC Markets. The company completed a $57.5 million initial public offering in January 2021, including full exercise of underwriters' over-allotment option; pursued a business combination with Aerami Therapeutics Holdings Inc., a biopharmaceutical developer of inhaled therapies, announced in December 2021 but mutually terminated in March 2022, and a subsequent merger agreement with Clover Inc., a live streaming social entertainment platform, announced in September 2022 but cancelled prior to closing; announced a change in special meeting date and increased trust account contribution for an extension proposal in November 2022, followed by redemption of public shares in January 2023 without consummating an initial business combination, resulting in liquidation.
U.S. IPO Weekly Recap: The IPO Market Has No Time To RLX In A 6-IPO Week